Sell-side PT & Stock Update on Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX), AT&T Inc. (NYSE:T), Stryker Corporation (NYSE:SYK)

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) shares have a current ABR (average broker recommendation) of 2.02. This recommendation is offered by Zacks Research. The rating lands on a sliding numerical scale from 1 to 5. A recommendation of 5 would indicate a Strong Sell, and a 1 would signify a Strong Buy. The mean rating may help provide a general sense of analyst sentiment on company shares.

Sell-side analysts taken into consideration by Zacks have also provided price target estimates on shares of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX). The highest current target is $17. The lowest price target out of the polled analysts is presently $10. The consensus target price is currently noted at $14.681. Analysts may employ various techniques to help predict future stock price levels.

On the earnings front, Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) is expected to post quarterly earnings per share of $0.09. This is the current consensus figure provided by Zacks. Investors and analysts will be looking for the company to next post earnings on or around 2017-05-04. Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) most recently reported quarterly EPS of $0.1 for the quarter ending 2016-12-31. The gap between the actual and the projected estimate leading up to earnings created a surprise factor of -16.67%.

For the current quarter, analysts are expecting AT&T Inc. (NYSE:T) to report EPS of $0.74. This consensus estimate is provided by Zacks Research. After the period that ended on 2017-03-31, AT&T Inc. (NYSE:T) reported an EPS actual of $0.74. The difference between the actual and estimate resulted in a surprise factor of 0%. The company is expected to release their next earnings report on or around 2017-07-20. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.

Shares of AT&T Inc. (NYSE:T) have a current ABR or average broker rating of 2.45. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.

Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of AT&T Inc. (NYSE:T) is $42.841. The top analyst target is $48, and the lowest target is $40 on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.

In the most recent session, Stryker Corporation (NYSE:SYK) shares have traded +0.74%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $4.18 away from the 50-day moving average of $132.19 and $13.94 away from the 200-day moving average of $122.43. From a different angle, the stock has been recently recorded -0.17% off of the 52-week high of 136.60 and +28.07% removed from the 52-week low of 106.48. 

Currently, Stryker Corporation has a price to earnings ratio of 30.64. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 2.17.

Price Target Update

Analysts polled by Thomson Reuters have set a consensus target price of $142.10 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.

Leave a Comment